Financial Performance - The company expects a net loss of between 15 million and 21 million yuan for the fiscal year 2024, compared to a profit of 243.07 million yuan in the same period last year, indicating a decline of 106.17% to 108.64%[3] - The expected loss for net profit after deducting non-recurring gains and losses is between 22.6 million and 28.6 million yuan, down from a profit of 231.97 million yuan last year, reflecting a decline of 109.74% to 112.33%[3] Market Conditions - The significant decline in overall operating performance is primarily due to a sharp change in market demand for certain antiviral raw material products, leading to a noticeable decrease in sales revenue[5] - The company also experienced a decline in product prices, which resulted in a significant drop in gross profit margins, further impacting overall profitability[5] Financial Reporting - The financial data presented is preliminary and has not been audited by an external accounting firm, with detailed financial results to be disclosed in the 2024 annual report[7]
拓新药业(301089) - 2024 Q4 - 年度业绩预告